{"links":{"feed":"https://www.erudio.com/reports/nct02950766/feed.json","html":"https://www.erudio.com/reports/nct02950766","json":"https://www.erudio.com/reports/nct02950766.json","markdown":"https://www.erudio.com/reports/nct02950766.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"nct02950766"}},"request":"https://www.erudio.com/contact?report=nct02950766"},"offer":{"cited_clinicians":13,"cited_commentary_sources":23,"verified_hcp_statements":115,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":15},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"nct02950766"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=nct02950766","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/nct02950766","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 115 verified statements · 40 from 13 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-21T20:19:46.267596Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":2},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Number of participants with dose-limiting toxicity (DLT) experienced within 49 days (7 weeks) of treatment initiation as assessed by CTCAE v4.0"},{"claim_count":12,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":10,"title":"Secondary endpoint: Number of participants with NeoVax induced IFN γ (interferon γ) T-cell Response against neoepitopes measured by ELISPOT at week 16"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":0,"title":"Secondary endpoint: Number of participants alive at 2 years"},{"claim_count":12,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":6,"title":"Population and setting"},{"claim_count":8,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":6,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":5,"title":"Safety and tolerability"},{"claim_count":11,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":7,"title":"Design and conduct"},{"claim_count":30,"coverage":"discussed","id":"A1","source_count":21,"title":"How clinical authors and accounts interpret adjuvant promise"},{"claim_count":5,"coverage":"discussed","id":"A2","source_count":3,"title":"Why speakers distinguish neoantigen selection from earlier RCC vaccines"},{"claim_count":16,"coverage":"discussed","id":"A3","source_count":5,"title":"How speakers explain tumor-directed immune activity"},{"claim_count":8,"coverage":"discussed","id":"A4","source_count":4,"title":"How accounts weigh personalized manufacture and alternative platforms"},{"claim_count":9,"coverage":"discussed","id":"A5","source_count":6,"title":"How speakers frame randomized add-on development and sequencing"},{"claim_count":7,"coverage":"discussed","id":"A6","source_count":2,"title":"How accounts discuss affordability, navigation and patient support"},{"claim_count":8,"coverage":"discussed","id":"A7","source_count":1,"title":"How accounts connect vaccine promise with research-funding concerns"},{"claim_count":10,"coverage":"discussed","id":"A8","source_count":3,"title":"How accounts frame therapeutic vaccination and cross-cancer extrapolation"}],"counts":{"beyond_population_findings":3,"beyond_population_statements":12,"cited_clinicians":13,"cited_clinicians_by_role":{"physician":4,"physician, Cardiology":1,"physician, Medical oncology":7,"physician, Radiation oncology":1},"cited_physicians":13,"cited_sources":24,"claims_by_expression_type":{"comparison":12,"experience":2,"interpretation":34,"opinion":34,"primary_context":4,"restatement":17,"uncertainty":3,"unspecified":9},"claims_by_kind":{"objective_result":2,"protocol_statement":2,"publication_statement":24,"source_observation":87},"clinician_statements":40,"evidence_units":111,"findings":9,"organisational_accounts":2,"people_cited":22,"people_identity_verified":15,"people_total":22,"screened_sources":37,"verified_claims":115},"findings_index":[{"cited_clinicians":5,"id":"F1","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":3,"views":7},"limitations":3,"links":{"context":1,"support":14},"ma_question":true,"named_voices":7,"passages":12,"sources":9,"sources_by_kind":{"commentary":8,"publication":1}},"title":"Adjuvant RCC vaccine: most speakers welcome it, and most highlight efficacy","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-d36a121fa6764cb41f1f","claim-07a03b7f93b604a6c3ce","claim-dc0c66dc5f54daf23ab1","claim-41fc62633134450014e6","claim-d5a9d8eeffa9d820648c"],"clause":"most highlight efficacy","holders":5},"cited_claim_ids":["claim-f949e00cbb28eabb08fb","claim-d36a121fa6764cb41f1f","claim-07a03b7f93b604a6c3ce","claim-41fc62633134450014e6","claim-d5a9d8eeffa9d820648c","claim-b85a7827c202d21cf93e"],"clinicians":false,"holders":6,"speakers":7,"view":"reading"},"evidence_line":"11 statements from 7 speakers in 9 sources","holder_line":"6 of the 7 named speakers in this finding hold this view; 5 of the 7 hold its caveat, “most highlight efficacy”"},{"cited_clinicians":3,"id":"F2","structure":{"claims":13,"claims_by_group":{"comparisons":4,"experience":0,"questions":0,"restated":2,"views":7},"limitations":3,"links":{"context":0,"support":15},"ma_question":true,"named_voices":3,"passages":9,"sources":5,"sources_by_kind":{"commentary":2,"media":2,"publication":1}},"title":"RCC vaccines: how most clinicians distinguish neoantigen targeting from older approaches","title_holders":{"cited_claim_ids":["claim-c880fe5cca9b83b27997","claim-84751d4e92c561e899f5","claim-014c905973cbe8218951"],"clinicians":true,"holders":2,"speakers":3,"view":"reading"},"evidence_line":"13 statements from 3 speakers in 5 sources, 2 of them podcasts or videos","holder_line":"2 of the 3 named speakers in this finding hold this view, each a confirmed clinician"},{"cited_clinicians":2,"id":"F3","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":2,"views":4},"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":2,"passages":5,"sources":4,"sources_by_kind":{"commentary":2,"media":1,"publication":1}},"title":"Adjuvant RCC vaccination: what clinicians highlight about the toxicity burden","title_holders":{"cited_claim_ids":["claim-97d5302ccbcffd18ca20","claim-41fc62633134450014e6"],"clinicians":true,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"7 statements from 2 speakers in 4 sources, 1 of them a podcast or video","holder_line":"2 of the 2 named speakers in this finding hold this view, each a confirmed clinician"},{"cited_clinicians":2,"id":"F4","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":2,"questions":0,"restated":4,"views":0},"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":2,"passages":4,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"publication":1}},"title":"RCC protein vaccines: clinicians see feasibility but one flags complexity","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-58bde8dd7a47e43a32fb"],"clause":"one flags complexity","holders":1},"cited_claim_ids":["claim-f0f201ca347d9ec85c99","claim-5cfc9b2d333d22ed2edc","claim-edca450a5048e345430d"],"clinicians":true,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"6 statements from 2 speakers in 3 sources, 1 of them a podcast or video","holder_line":"2 of the 2 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one flags complexity”"},{"cited_clinicians":0,"id":"F5","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":7},"limitations":3,"links":{"context":1,"support":8},"ma_question":true,"named_voices":5,"passages":9,"sources":1,"sources_by_kind":{"commentary":1}},"title":"RCC vaccine research: why most speakers fear political and funding threats","title_holders":{"cited_claim_ids":["claim-974da43e823fd3dc339b","claim-b86cdec26e749655aa40","claim-d452192c04c95f368f00","claim-004584ecd98f6c952fc7","claim-c843c2702310dcbfe21a","claim-22cbc6fa5693f1cbd6b1"],"clinicians":false,"holders":4,"speakers":5,"view":"reading"},"evidence_line":"7 statements from 5 speakers in 1 source","holder_line":"4 of the 5 named speakers in this finding hold this view"},{"cited_clinicians":0,"id":"F9","structure":{"claims":4,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":3},"limitations":3,"links":{"context":2,"support":4},"ma_question":true,"named_voices":1,"passages":6,"sources":1,"sources_by_kind":{"commentary":1}},"title":"RCC vaccines: a speaker favors affordability, offers trial help if wanted","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-a884307a92c37687c634"],"clause":"offer trial help if wanted","holders":1},"cited_claim_ids":["claim-8464690a168110ba6d29"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"4 statements from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view; 1 of them holds its caveat, “offer trial help if wanted”"},{"cited_clinicians":2,"id":"F6","population":"beyond","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":1,"views":4},"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":2,"passages":4,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"publication":1}},"title":"RCC vaccines: why clinicians look to randomized testing with adjuvant pembrolizumab","title_holders":{"cited_claim_ids":["claim-1dd7e96c4da28e9c40b8","claim-4b46751a734d5b9086df"],"clinicians":true,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"7 statements from 2 speakers in 3 sources, 1 of them a podcast or video","holder_line":"2 of the 2 named speakers in this finding hold this view, each a confirmed clinician"},{"cited_clinicians":1,"id":"F7","population":"beyond","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":4,"views":0},"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":1,"passages":3,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"RCC vaccination after surgery: what speakers say","evidence_line":"5 statements from 1 speaker in 2 sources, 1 of them a podcast or video"},{"cited_clinicians":0,"id":"F8","population":"beyond","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":0,"views":0},"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":0,"passages":2,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"Non-clear-cell RCC: why a speaker flags uncertainty about vaccine-trial inclusion","title_holders":{"cited_claim_ids":["claim-41407adc7a03521f27b6"],"clinicians":false,"holders":0,"speakers":0,"view":"reading"},"evidence_line":"2 statements in 2 sources","holder_line":"No named speaker is counted in this finding: its title's view comes from speakers the source does not name"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Clinicians welcome adjuvant vaccination; one describes it as effective therapy"},{"id":"section-2","level":2,"title":"Speakers distinguish neoantigen targeting from checkpoint release and older vaccine approaches"},{"id":"section-3","level":2,"title":"One clinician sees a low-toxicity option; a patient account describes treatment burden"},{"id":"section-4","level":2,"title":"One interview describes protein-vaccine manufacture as difficult despite successful personalization"},{"id":"section-5","level":2,"title":"Accounts fear political and funding decisions could halt vaccine research"},{"id":"section-6","level":2,"title":"One account prioritizes affordability and trial navigation; another asks about CAR-T"},{"id":"section-7","level":2,"title":"Beyond the trial population"},{"id":"section-8","level":3,"title":"Speakers highlight randomized testing of a vaccine added to adjuvant pembrolizumab"},{"id":"section-9","level":3,"title":"Whether a relayed cross-cancer mRNA-vaccine comparison informs this postoperative RCC decision"},{"id":"section-10","level":3,"title":"One account flags uncertainty about studying non-clear-cell RCC"},{"id":"section-11","level":2,"title":"What the reviewed discussion can and cannot represent"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, single group, phase1","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Number of participants with dose-limiting toxicity (DLT) experienced within 49 days (7 weeks) of treatment initiation as assessed by CTCAE v4.0"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":2}],"id":"T2","label":"Secondary endpoint: Number of participants with NeoVax induced IFN γ (interferon γ) T-cell Response against neoepitopes measured by ELISPOT at week 16"},{"findings":[],"id":"T3","label":"Secondary endpoint: Number of participants alive at 2 years"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F4","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":1}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-21T20:19:46.267596Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-21T20:32:51Z","record_hash":"8fad05c864906d1f0a88d794b4bab2961f12dad489f2aaa958850460ee027b73","release_hash":"23d7f463b670502a7f89d581f67590cdb10bcc03879d56b1e64c475fdf153b14","report_id":"erudio-nct02950766","run_id":"ce13d0f0-a931-4b16-af27-62dd460bcdf3","schema_version":"5.0","slug":"nct02950766","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"The clinicians cited see NCT02950766 as support for pursuing personalized vaccination, pointing to tumor-directed immune responses, but a medical oncologist interprets the findings more definitively as showing clinical benefit. Another medical oncologist judges tolerability favorably, alongside a relayed patient experience describing treatment as difficult at times. Comparative benefit and uncommon harms remain beyond what the sources reviewed for this edition can establish.","examples":[],"meta_description":"37 sources screened · 115 verified statements (40 from clinicians verified by NPI or staff page) from 24 sources · 9 findings. Updated Nov 21, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-21T20:32:51Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":37},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","26 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 34 sources about other trials or topics are not included; 2 sources that may describe the trial without naming it were not read; discussion that uses a name the trial shares with other things, without the trial's condition or setting, may be missing.","The central published experience is small and nonrandomized. It cannot establish comparative efficacy or reliably characterize uncommon harms; the higher local-ipilimumab-dose cohort was not part of the reported analysis.","The sources reviewed are not a representative sample of HCP practice. Reposts and cross-platform repeats do not add independent judgments, and source-described trial contributors are not external validation.","Clinical roles are not established for several named social accounts, and unidentified spoken passages cannot be assigned to a person from a programme title, description or participant list.","No separate protocol or NeoVax-specific regulatory label was available in the sources reviewed. This report does not establish regulatory status, reimbursement or routine access.","Follow-up study descriptions retain their own publication dates and accrual wording. Without a verified shared study identifier, they should not be treated as a single timeline, a change of mind or follow-up efficacy evidence.","Cross-cancer mRNA comparisons, non-clear-cell applicability, comparative production costs and individual trial eligibility remain unresolved in these sources."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":6,"linkedin_post":0,"other":0,"podcast":0,"publication":1,"registry":0,"regulatory":0,"x_thread":14,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":23,"results":1},"count":24,"evidence_window":{"end":"2026-08-11","start":"2021-08-25"},"retrieval_snapshot":"2026-11-21T19:18:52.886757Z","timeline":[{"count":1,"week":"2021-W34"},{"count":11,"week":"2025-W06"},{"count":1,"week":"2025-W07"},{"count":4,"week":"2025-W08"},{"count":1,"week":"2025-W09"},{"count":1,"week":"2025-W10"},{"count":1,"week":"2025-W12"},{"count":1,"week":"2025-W21"},{"count":1,"week":"2025-W30"},{"count":1,"week":"2026-W01"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W33"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT02950766:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02950766:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:39910301","quote_policy":"no_derivatives"},{"id":"openfda:2265ef30-253e-11df-8a39-0800200c9a66:20260820","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4ki6jqputt5kvlf65ul7dwpz-3lhsrrkuzt22i","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-6vwezbhj7wwowu4sbur5npjk-3lhh7vobaks2k","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-dm23ygqhglasejxum6fqjnip-3lojrvdrgwu2c","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-hvybly7ak5rfumcoeda5r4mx-3lhh4iiiaq22x","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-llgfbjvsqkaicezsf7mzjxr3-3lj3u3cxdck2h","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ogakdmlnkdx4iseoo2k7fcis-3lhhcoazx7c23","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-pwbuf4hieo24wlhs7d7fmfhl-3lihiojy3q22o","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-t45twttnbk7wmjtw6ofqcyse-3lhhby2xi2s2k","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1104475382718160896:df339a42-f526-4493-a87a-bfe96f21791d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1191432945661333505:1fa005cc-4e73-40ab-83e4-80970ea658b3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1349001333613891584:7f4d1fa5-979d-4c9a-a77d-e258820340aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1603115026268626944:bb2e127a-7ca2-44ce-83c0-8a47c5300d62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1679857892269105157:d1cc43d8-cb44-4a3b-b649-e18a24f31c5c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1811774685664711157:1ca7089e-e65d-4b41-9f70-9e2bd22203ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1887183608168796450:7085b2dd-a27e-4ae5-9ecd-45dea5ed2a88","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1887194178913984853:9e5803a3-caf9-4cbb-822a-94d9977a794d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1887195716998864960:f4e51a73-fafa-4c9b-bf97-02737d75898e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1887198291626209522:f4485185-10c2-4a19-99d2-ef6d2169f29c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1887199026694455690:096b8f30-353b-44f5-9f3c-3087b76aeb98","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1887230073868009713:c5e4061d-cd45-4a56-be62-2f2fec13bb3c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1887321730491846839:602229a6-36c0-4ebb-bb9b-0776ddeac5d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1887321822993240558:3461f0d3-0727-4376-9779-31d0df2a5c5b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1887637405198389327:16631277-15cd-4460-a794-83955dd8283a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1887845321662738460:ec12dd58-c112-4743-abce-2f54223d8c22","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1891827508175098237:c027757a-bf43-439f-900d-f49675719812","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1892296035730673901:41962e95-115c-45f7-9ee0-eb97517fecd1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1892513392583229594:023f4c08-bcf7-4b79-be27-047bc56c1fa3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925461443970732278:b27b3d3e-a40f-4275-8d4d-78822f0af7c1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1969053959869317517:1cd1faf1-c32c-484d-9caa-a518fc43552f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2005585413021610202:5e9291f6-9e5e-4b34-9a40-0d07284c03bb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056661071620968462:be186af5-4fbd-431b-b8a7-387451a99990","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058914935862948270:531c8003-ffe2-46c1-bbc4-486bbc3ab2aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2087147518928756890:e4063b4b-2287-4e1e-82f4-1976c87b3171","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2119876249459798199:68703afe-4fe1-489c-8ef1-34531c0bcc3e","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:PAeW4u-yhUc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:PXd-X8rtjhY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:tZRC_6z3pUc","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":8,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":26,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":37},"count":37,"evidence_window":{"end":"2026-11-09","start":"2019-03-09"},"retrieval_snapshot":"2026-11-21T19:18:52.886757Z","timeline":[{"count":1,"week":"2019-W10"},{"count":1,"week":"2019-W45"},{"count":1,"week":"2021-W02"},{"count":1,"week":"2021-W34"},{"count":1,"week":"2022-W50"},{"count":1,"week":"2023-W28"},{"count":1,"week":"2024-W28"},{"count":14,"week":"2025-W06"},{"count":1,"week":"2025-W07"},{"count":5,"week":"2025-W08"},{"count":1,"week":"2025-W09"},{"count":1,"week":"2025-W10"},{"count":1,"week":"2025-W12"},{"count":1,"week":"2025-W19"},{"count":1,"week":"2025-W21"},{"count":1,"week":"2025-W30"},{"count":1,"week":"2025-W38"},{"count":1,"week":"2026-W01"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W33"},{"count":1,"week":"2026-W46"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":34,"linkedin_post":0,"other":0,"podcast":0,"publication":28,"registry":0,"regulatory":0,"x_thread":34,"x_video":0,"youtube":19}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: neovax","status":"unmapped"},{"brand_names":["Yervoy"],"label":"ipilimumab","slug":"ipilimumab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Renal cell carcinoma","slug":"renal-cell-carcinoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"aliases":["NeoVax Plus Ipilimumab in Renal Cell Carcinoma","A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma"],"brief_title":"NeoVax Plus Ipilimumab in Renal Cell Carcinoma","collaborators":["Bristol-Myers Squibb","Oncovir, Inc."],"conditions":["Kidney Cancer"],"display_condition":"high-risk renal cell carcinoma","display_interventions":[["NeoVax","ipilimumab"],["NeoVax"]],"enrollment":{"count":19,"type":"ESTIMATED"},"interventions":[{"name":"NeoVax","synonyms":["neoantigen vaccine"],"type":"DRUG"},{"name":"Ipilimumab","synonyms":["Yervoy"],"type":"DRUG"}],"nct_id":"NCT02950766","official_title":"A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE1"],"primary_completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Number of participants with dose-limiting toxicity (DLT) experienced within 49 days (7 weeks) of treatment initiation as assessed by CTCAE v4.0","timeFrame":"49 days"}],"registered_date":{"date":"2016-11-01","type":"ESTIMATED"},"registry_last_updated":"2026-02-03","registry_url":"https://clinicaltrials.gov/study/NCT02950766","short_name":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"short_name_basis":{"reason":"No registry acronym or sponsor study code.","status":"unavailable"},"sponsor":"Patrick Ott, MD, PhD","start_date":{"date":"2019-03-03","type":"ACTUAL"},"study_design":"interventional, non randomized, single group, phase1","study_ids":[{"id":"16-097","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}